AUTHORS
Leonardo R. Brandao, MD, MSc, Ellis Neufeld, MD, PhD2, Madhvi Rajpurkar, MD3, Guy Young, MD4, Jenny Y Zhou, MD5, Maral DerSarkissian, PhD6, Jessica Smith7, Henrik Sliwka, MD8, Angela Simon9
AFFILIATIONS
1 Dalla Lana School of Public Health, Toronto, Ontario, Canada, The Hospital for Sick Children, Toronto, Ontario, Canada
2 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
3 Central Michigan University, Wayne State University, and Children’s Hospital of Michigan, Detroit, Michigan, United States
4 Children’s Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, United States
5 UC San Diego Health and UC San Diego School of Medicine, San Diego, California, United States
6 Analysis Group, Los Angeles, California, United States
7 Analysis Group, Los Angeles, California, United States
8 Takeda Pharmaceutical Company, Zurich, Switzerland
9 Takeda Pharmaceutical Company, Cambridge, Massachusetts, United States
ABSTRACT
Introduction
More than 40 years after its original description, severe congenital protein C deficiency (SCPCD) remains a potentially fatal condition. While acute management is well established, optimal long-term management to prevent life-altering sequelae remains uncertain. A plasma-derived protein C (PC) concentrate (Baxalta, Inc., a Takeda company) was approved in the US in 2007 for patients with SCPCD, but real-world evidence on its use as long-term prophylaxis (LTP) is limited. This study aimed to describe patient characteristics, longitudinal treatment patterns, and clinical outcomes in patients with SCPCD receiving PC concentrate with or without anticoagulation as LTP in the US.
Methods
PROaCtive was a retrospective, observational, longitudinal chart review study conducted from July 3 to November 21, 2025. Patients with SCPCD who initiated PC concentrate LTP on or after March 30, 2007 in the US were included in the study cohort. The index date was defined as the LTP initiation date. Treatment episodes were defined as the time from initiation to discontinuation of PC concentrate as LTP or end of follow-up, whichever occurred first. Data were extracted for patient demographics and clinical characteristics at baseline (≤12 months before index), and for treatment patterns and clinical outcomes during follow-up (≥12 months from index until the earliest of chart abstraction, loss to follow-up, or death). This study was funded by Takeda.
Results
Twenty-nine treatment episodes were observed among 26 patients (77% male; 85% White or Caucasian) from multiple institutions. The median (first quartile [Q1], third quartile [Q3]) age at SCPCD diagnosis and index was 0.1 (0.0, 1.8) years and 1.4 (0.0, 13.2) years, respectively; median time from diagnosis to index was 0.4 (0.0, 5.6) years. Twenty patients (77%) had homozygous, and 6 patients (23%) had compound heterozygous PROC gene mutations. The median (Q1, Q3) PC level at diagnosis and index was 1.5% (1.0, 3.0) and 2.0% (1.0, 8.0), respectively. The median (Q1, Q3) duration of LTP treatment episodes was 2.0 (1.1, 6.4) years. At LTP initiation, PC concentrate was mostly administered intravenously (86%), with 40–60 IU/kg and every 12 hours as the most common dose and dosing interval, respectively. The median (Q1, Q3) PC level during LTP treatment episodes was 40.0% (20.0, 60.0). Concomitant therapy was used in 45% of treatment episodes (direct oral anticoagulants, 21%; heparin/low-molecular-weight heparin, 21%; vitamin K antagonists, 7%; fresh frozen plasma, 3%). The most commonly cited reason for the use of both direct oral anticoagulants (83%) and the other concomitant therapies (71%) was to treat thrombotic episodes. Changes in PC concentrate dose or dosing interval were observed in 31% of treatment episodes, with the most common reason being patient or caregiver’s preference (44%). Ten treatment episodes (35%) were discontinued, mainly owing to patient preference (60%). The median (Q1, Q3) follow-up duration was 3.3 (2.0, 8.3) years, during which thrombotic events occurred in 3 patients (12%), a separate central venous catheter-related thrombosis occurred in 1 patient (4%), skin induration occurred in 5 patients (19%), and failure to achieve targeted PC trough levels occurred in 7 patients (27%). One death (4%) occurred, approximately 17 years post-index. Event-free rates (95% confidence intervals) at 5 years were 92% (73–98) for thrombotic events, 90% (47–99) for recurrent purpura fulminans, 89% (62–97) for skin necrosis, 89% (43–98) for blindness/impaired vision, 87% (58–97) for skin grafting, 79% (45–93) for surgical procedures, and 100% (100–100) for all-cause death.
Conclusion
In this large, real-world dataset of patients with SCPCD treated with PC concentrate, LTP was started a median of 0.4 years after diagnosis. In the US, LTP was conducted mostly with IV PC replacement and demonstrated sustained durability, with low rates of thrombotic events and mortality. Adjustments to dose and dosing interval highlight the need for individualized treatment approaches in response to the hemostatic variability prevalent in patients with SCPCD.
DISCLOSURES
Leonardo R. Brandao, MD, MSc: Takeda - Consultancy (Includes expert testimony)